Halozyme (NASDAQ:HALO) stock surged after 2025 guidance upgrade and a Morgan Stanley rating boost. Read more here.

Halozyme Therapeutics Inc. HALO) on Tuesday reported second-quarter net income of $165.2 million. On a per-share basis, the ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2025, provided an update on its recent ...

Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

Analysts expect Halozyme Therapeutics to report an earnings per share (EPS) of $1.20. Anticipation surrounds Halozyme ...

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $75 from $72 and keeps a Buy rating on the shares ...

The company raised its full-year 2025 guidance, now expecting earnings per share of $6.00-$6.40, well above the consensus estimate of $5.40. Halozyme also increased its revenue forecast to $1.27-1.35 ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Here are a few recent upgrades you may want to pay attention to. Palantir Technologies Palantir Technologies (NYSE: PLTR) ...

The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The ...